AEON vs CUBE · P/E 0.0, $8.6M cap vs P/E 25, rev $1.07B
AEON Biopharma, Inc. (AEON) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
AEON Biopharma, Inc. (AEON) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
AEON does not have a complete income-statement cache yet.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
AEON currently screens at market cap $8.6M and trailing P/E 0.0. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the AEON and CUBE stock pages for the full models.
Not investment advice.